Peripheral Interventions

The Eluvia™ Drug-Eluting Vascular Stent System is specifically developed for the treatment of peripheral artery disease (PAD) in the superficial femoral artery (SFA) and proximal popliteal artery (PPA). The Eluvia stent utilizes a drug-polymer combination to offer sustained release of the drug paclitaxel for a one-year timeframe, designed to prevent tissue regrowth that might otherwise block the stented artery. The Eluvia stent was approved by the FDA based on findings from the IMPERIAL trial, in which the Eluvia stent demonstrated superior results in the first superficial femoral artery head-to-head drug-eluting stent trial.

The Ranger™ Drug-Coated Balloon was developed for the treatment of patients with peripheral artery disease (PAD) in the superficial femoral artery (SFA) and proximal popliteal artery (PPA). It was designed with a low therapeutic drug dose and proprietary coating which efficiently transfers the drug into the diseased tissue, resulting in high primary patency rates and low systemic drug exposure for patients. The low-profile platform of the balloon also assists clinicians in performing streamlined procedures and navigating through challenging anatomy in order to deliver consistent therapy.

The Embold™ Detachable Coil System is a portfolio of three fully retractable coils built to maximize procedural flexibility and reliability. Used for arterial and venous embolizations in the peripheral vasculature of adults, the Embold coils take coiling simplicity to a new level, offering multi-catheter compatibility to lessen procedure time and complexity; a nitinol delivery system that’s resistant to kinking and premature detachment; handle-free detachment to reduce procedure steps and cost; and occlusion power for more certainty.

TheraSphere is a radioembolization treatment for patients diagnosed with primary liver cancer and metastatic liver cancer.* A targeted therapy, TheraSphere consists of millions of glass microspheres containing radioactive yttrium-90 that are delivered into the hepatic artery to selectively target and destroy tumor cells while minimizing distribution and impact to normal tissue. The radioactive microspheres continue to deliver radiation to the tumor over the course of several weeks after treatment.

The EKOS™ Endovascular System is the first endovascular device cleared by the FDA for the treatment of pulmonary embolism (PE), which is designed to leverage targeted ultrasound power in combination with clot-dissolving drugs to restore blood flow in patients with PE.

The OBSIDIO™ Conformable Embolic is used to embolize blood vessels to stop blood from flowing to a specific area. Through a process called shear thinning, it starts as an injectable soft solid, flows as a liquid when force is applied, and returns to a soft solid to occlude the vessel. It is the first and only conformable embolic indicated to treat bleeds and tumors in the peripheral vasculature.